The EVM401 Series comprises proprietary, non-hallucinogenic mescaline-derived compounds designed to promote neuroplasticity for the potential treatment of psychiatric and neurological disorders.

The patent application, entitled "Substituted N-Propylamine Fused Heterocyclic Mescaline Derivatives," represents the third U.S. patent allowance within Enveric's EVM401 Series. Once issued, the patent is expected to strengthen the Company's growing intellectual property estate with composition-of-matter claims covering a unique series of proprietary, methylone-inspired benzodioxole analogs designed as non-hallucinogenic neuroplastogens for the potential treatment of PTSD and other psychiatric and neurological conditions.

"Building a robust intellectual property portfolio around differentiated neuroplastogenic compounds remains a central component of Enveric's strategy," said Joseph Tucker, Ph.D., Director and Chief Executive Officer of Enveric. "As recent clinical data reported by others in the literature continue to support further evaluation of methylone-based therapies for PTSD, we believe this latest patent allowance further strengthens the value of our EVM401 Series and our differentiated approach to developing proprietary mescaline-derived compounds that preserve key pharmacophoric features associated with methylone while introducing novel structural modifications designed to reduce or eliminate hallucinogenic effects."

Unlike methylone, whose chemical structure resides in the public domain and lacks composition-of-matter patent protection, Enveric's proprietary analogs incorporate unique structural modifications to the benzodioxole ring that differentiate them from known molecules and allow for stronger intellectual property protection. In addition, these modifications may increase lipophilicity, facilitate penetration across the blood-brain barrier, and improve metabolic stability, offering the potential to support oral administration while preserving the neuroplastogenic profile.